Converge Bio Raises $25M for AI Drug Discovery with Backing from Top Meta and OpenAI Executives

When OpenAI executives put their own money into a biotech startup, that's a signal hard to ignore. Converge Bio — a young company in the AI-driven drug discovery space — just closed its Series A round at $25 million, assembling an impressive coalition of investors from the world of big technology around itself.

Bessemer Venture Partners led the round — one of Silicon Valley's oldest and most respected venture funds with a portfolio including Pinterest, Shopify, and Twilio. However, equally noteworthy is the composition of angel investors: among them are executives from Meta, OpenAI, and Wiz — an Israeli cybersecurity startup recently valued at $12 billion.

This combination of investors reflects a fundamental shift in how the technology community perceives biopharmaceuticals. Five years ago, drug development was considered too slow, regulated, and capital-intensive an industry for tech investors. Today, generative AI is changing the rules of the game.

Converge Bio operates in the AI drug discovery segment — the application of machine learning to accelerate the search for molecular candidates for future drugs. The traditional process takes years and costs billions of dollars. Algorithms can sift through millions of potential compounds, predict their properties, and filter out unpromising options at early stages.

The market for AI in pharmaceuticals is experiencing a boom. According to analysts, by 2030 its volume could reach $4 billion. Major players — Insilico Medicine, Recursion Pharmaceuticals, Exscientia — have already advanced AI-developed drugs into clinical trials. Converge Bio is entering the race with serious financial resources, but in a highly competitive field.

The participation of OpenAI executives is particularly symbolic. The company that created GPT-4 possesses unique expertise in large language models. Their interest in biotech may signal that the next breakthrough in AI will come not in text or image generation, but in molecular modeling.

For a Russian observer, the deal underscores the growing gap in funding for capital-intensive AI startups. While domestic biotech companies struggle for grants in tens of millions of rubles, their American competitors are attracting comparable sums in dollars — with access to the best GPU clusters and clinical trial data.

$25 million is fuel for a race whose outcome will determine who develops next-generation drugs. Converge Bio received not just money, but access to a network of contacts among the technology elite. Now it's up to the scientists and algorithms.